Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2006-09-26
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07112602
ABSTRACT:
The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus
patent: 3563986 (1971-02-01), Frankus
patent: 3625946 (1971-12-01), Heinrich et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4605661 (1986-08-01), Hirsch et al.
patent: 4916144 (1990-04-01), Strehlke et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5405855 (1995-04-01), Andrulis, Jr.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5443824 (1995-08-01), Piacquadio
patent: 5502066 (1996-03-01), Heinemann
patent: 5605684 (1997-02-01), Piacquadio
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D′Amato
patent: 5643915 (1997-07-01), Andrulis, Jr. et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 5919790 (1999-07-01), Allen et al.
patent: 6020358 (2000-02-01), Mullet et al.
patent: 2002/0061923 (2002-05-01), D′Amato
patent: 1182709 (1970-03-01), None
patent: 1182709 (1970-03-01), None
patent: 0 325 199 (1989-07-01), None
patent: 0 357 061 (1990-03-01), None
patent: 0 688 771 (1995-06-01), None
patent: 58-131978 (1983-08-01), None
patent: 63-119500 (1988-05-01), None
patent: WO 91/10424 (1991-07-01), None
patent: WO 92/14455 (1992-09-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/04533 (1995-02-01), None
Algire, 1945, “Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants,” J. Natl. Cancer Inst. pp. 73-85.
Allegri, 1964, “Confermata I'inefficacia della talidomides nella terapia dei tumori,” Gazzetta Medica Italiana pp. 124-127.
Ambs et al., 1997, “Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression,” FASEB J. 11:443-448.
Apt, 1995, “Effect of thalidmoide on the course of experimental Chagas' Disease,” BOI. Chil. Parasitol. 20(3):84-86.
Aronson et al., 1984, “Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures,” Arch. Dermatol. 120(11):1466-1470.
Bach et al., 1963, “Studies on the possible anti-neoplastic effect of thalidomide,” ACTA PathologicaET Microbiologica Scandinavica 59-491-499.
Bach et al., 1963, “Thalidomide in cancer chemotherapy,” Lancet 1:1271.
Bahmer, 1992, “Therapie bel lymphozytischer infiltration,” Der Hautarzt 43:663.
Balabanova et al., 1992, “Lupus erythermatosus hypertrophicus et profundus, ” Z. Hautkr 67(9):812-815.
Barnes. et al., “Tumor Necrosis Factor Production in Patients with Leprosy”,Infection and Immunity, VoI. 60 No. 4, pp. 1441-1446 (1992).
Barnhill, et al., “Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various other Conditions”,J. Am. Acad. Dermatol., vol. 7, No. 3, pp. 317-323-(1982).
Barnhill, R. et al., 1984, “Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytres and Monocytes”, J.A& Acad. Derm., vol. 11, No. 5, Part 1, pp. 814-819.
Barriere, H., “Traitement par la thalidomide”,La Presse Mkdicale, vol. 12, No. 15, pp.963 (1983).
Bazzoli, et al., “The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt”,J. Embryol. Exp. Morph., vol. 41, pp. 125-135 (1977).
Beck, Jr. et al. “Vascular Development: Cellular and Molecular Regulation”,The FASEB Journal, vol. 11, pp. 365-374 (1997).
Beccerica, E., “L'approccio terapeutico al paziente anziano con artrite reumatoide”,Clin. Ter., vol. 122, pp. 289-298 (1987).
Belaube, P. et al., 1983, “Should Thalidomide be Rehabilitated?”,Sem. Hop. Paris, vol. 59, No. 45, pp. 3101-3104.
Bensinger, W.I., “Supportive Care in Marrow Transplantation”,Curr. Opin. Oncol., vol. 4, No. 4, pp. 614-623 (1992).
Bernal, et al., “Cellular Immune Effects of Thalidomide in Actinic Prurigo”,Int'l. J, of Dermat., vol. 31, No. 8, pp. 599-600 (1992).
Blair, R. et al., “Human Mast Cells Stimulate Vascular Tube Formation”,Journal of Clinical Investigation, vol. 99, No. 11, pp. 2691-2700 (1997).
Blaschke, V. et al., Chromatographische Racernattrennung von Thalidomid und teratogene Wirkung der Enantiomere,Arzneimittel Forsch./Dru,q Res., vol. 29, No. 11, pp. 1640-1642 (1979).
Bonifacino, J. et al., “A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum”,Science, vol. 2, pp. 79-80 (1990).
Bonnetblanc, et al., “Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study”,Dermatology, vol. 193, No. 4, pp. 321-323 (1996).
Boodman, S.G., “Questions About a Popular Prenatal Test”,The Washington Post(1992).
Bowers, et al., “Effect of Thalidomide on Orogenital Ulceration”,Br. Med. Journ., vol. 287, No. 6395, pp. 799-800 (1983).
Braun et al., 1981, “Thalidomide metabolite inhibits tumor cell attachment to concanavalin a coated surfaces,” Biochem. Biophys. Res. Comm. 98(4):1029-1034.
Brem et al., 1991, “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas,” J. Neurosurg. 74:441-446.
Bressler et al., 1992, “Clinicopathologic Correlation of occult choroidal neovascularization in age-related mascular degeneration,” Arch. Opthamol. 110:827.
Brodthagen, 1985, “Significant response of oral aphthosis to thalidomide treatment,” J. Am. Acad. Dermaol. 13(3):509.
Brovarone et al., 1991, “Occhio e gravidanza,” Minerva Ginecol 43:141-167.
Browne et al., 1991, “Expression of recombinant human plasminogen and aglycoplasminogen in HeLa cells,” Fibrinolysis 5:257-260.
Bubl et al., 1993, “Dysphagia in dermatologic disease,” Dysphagia 8(2):85-90.
Buckley et al., 1990, “Pyoderma gangrenosum with severe pharyngeal ulceration,” J. Royal Soc. Med. 83:590-591.
Buelens, 1967, Treatment of a greade II astrocytoma with thalidomide (Phthalylglutamic acid imide) [Behandlung eines astrocytoms II. Grades mit thaliomid (N-Phthalyglutaminsaureimid)], Arzneim-Forsch., 17(5):646-648.
Bullock, 1986, “The clinical significance of erythema nodosum,” Hosp. Pract. 21(3):102E-2H, 102K-2L, 102Q-2R pas.
Burger et al., 1992, “Epidermolysis bullosa acquisita a rare late complication of allogeneic bone marrow transplantation?” Bone Marrow transplantation 9(2):139-141.
Burrows, 1993, “Thalidomide Modifies disease,” Brit. Med. J. 307(6909):939-940.
Buckley et al., 1990, “Pyoderma gangrenosum with severe pharyngeal ulceration,” J. Royal Soc. Med. 83:590-591.
Calnan et al., 1977, “Actinic prurigo (Hutchinson's Summer Prurugo),” Clin. Exp. Dermatol. 2(4):365-372.
Cant, J.S., “Minor Ocular Abnormalities Asso
D'Amato Robert J.
Fogler William
Green Shawn J.
Madsen John W.
Papathanassiu Adonia E.
Day Jones
The Children's Medical Center Corporation
LandOfFree
Methods of treating undesired angiogenesis with 2-methyl-EM-138 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating undesired angiogenesis with 2-methyl-EM-138, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating undesired angiogenesis with 2-methyl-EM-138 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3570361